prix_galien_2011_sponsorship_brochure
Prix Galien 2011 sponsorship brochure
Hotels, Convention Centers and Convention & Visitor Bureaus
Pharmaceutical Executive Digital Edition - February 2011
The Promise Of Translational Medicine
The Building Block of Drug Discovery
With Francis Collins now calling the shots at NIH, will be be able to deliver on the innovations behind the genome?
Malta: A healthy location for the pharmaceutical industry
The mediterranean nation has endeared itself to foreign businesses over the past decades, adtively positioning itself as an appealing epicenter of global pharma interest
revised_edit_cal_12_7_10
PharmExec edit calendar revised and smaller size
Taiwan: Pharma at the Tipping Point
After many years of building up an impressive resource base, the industry is finally ready to take advantage of the wave of enthusiasm and interest surounding pharma and biotech that is sweeping the nation
june_2010_sworn_statement
June 2010 Sworn Statement
Country Report: The Philippines
Once silent, an emerging market raises its voice
pharm_exec_2011_online_rates
PharmExec 2011 online e-media rates
EPL 2010
Community: The Business of Life
Adam Smith's theory of the uncompromising market may set the tone for today's capitalism, but we forget that his first work,"The Theory of Moral Sentiments," made 'bettering the human condition' the basis from which all productive commerce flows.
FDA Extends Deadline for Avastin Review
September 21, 2010.
William Looney
Roche Plans Business Makeover
September 08, 2010.
The Coming Second Act
Reinvention takes more than a pithy redraft of the strategy plan or mission statement; money, a change in business culture, and the mindset of thousands of employees is required too
Actos Deemed as Safe as Avandia
Results from a new study reveal that patients taking Takeda's diabetes treatment Actos have the same rate and kind of side effects as GSK's embattled Avandia. Is this a good sign?
Lilly Kills Two Alzheimer's Trials
In a huge blow to Eli Lilly's Alzheimer's pipeline, the drug giant was forced to end two clinical trials due to the fact that the treatment was actually making patients' memory recall worse.
Amgen Head and Neck Cancer Study: A Disappointment
Head-and-neck cancer treatment trial flops in Phase 3 trials causing Amgen stock to drop. The first-line therapy failed first and secondary goals compared with chemotherapy alone.
NicOx Shutters HQ After Approval Fail
In the wake of FDA's refusal to approve the lead drug in NicOx's pipeline, the French firm has decided to close its US headquarters.
Learning to Weather a Storm
An industry struggling to meet expectations for new science may find the best strategy is the "controlled burn."
Sanofi Fights FDA Approval of Generic Lovenox
August 2, 2010.
GSK Rethinks Rep Compensation
Bonuses for reps at GlaxoSmithKline will soon be based on customer feedback and adherence to company policy, not sales targets. The move promises to transform sales & marketing, but the company offered few details about how the plan will be implemented.
Pfizer Suspends More Tanezunab Trials
Just weeks after ending tanezunab clinical studies in osteoarthritis patients, the drug giant is ceasing additional trials for two other indications.
UK Coalition Government Unveils Radical NHS Plans
July 14, 2010.
PhRMA Announces Billy Tauzin's Successor
John Castellani received the nod from PhRMA on Tuesday to take over the role of president and CEO in September.
FDA to Weigh In on Obesity Drug
Vivus's weight-loss drug Qnexa is heading into an FDA review with the backing of generally positive study data. Will FDA give the thumbs up? Depends on how severe it thinks the side effects are.
Jeff Schindler
Berwick Appointed Head of CMS
With a long, hard fight looming, President Obama decided to go around Congress to install Don Berwick, founder of the Institute for Healthcare Improvement, as the top administrator of the Centers for Medicaid and Medicare Services.
Q&A with Focus Reports team
Focus Reports discusses kep questions regarding France's pharma industry
